-data presented at the International Congress on Animal Reproduction in 
Vancouver, B.C.-

Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, 
technology-driven Canadian biopharmaceutical company, today shared preliminary 
data on an in-licensed superagonist hormone technology in bovine proof of 
concept studies. This technology was developed by Trophogen Inc., a U.S.-based 
biotechnology company. Bioniche signed an exclusive global veterinary license 
agreement with Trophogen in June, 2010. 

Several analogs produced with this recombinant follicle stimulating hormone 
(rFSH) technology have been tested over the past two years, and one has proven 
to be highly efficacious in the induction of multiple ovulations. A 
superovulatory response was induced with a single dose in beef cows treated 
three times consecutively. 

More studies are required to determine the optimal dosage of the technology 
both in beef and dairy cattle, and to determine the long-term effects of 
treating consecutively with rFSH more than three times. 

"These data are very encouraging," said Mr. Graeme McRae, President & CEO of 
Bioniche Life Sciences Inc., "Trophogen has developed a clearly superior 
recombinant FSH technology which will, over the coming years, be developed into 
a synthetic product containing no material of animal origin. No other animal 
health company has been able to successfully develop such a product." 

The Company's current FSH product, Folltropin®-V, is a global market leader. 
Folltropin®-V is used to superovulate reproductively mature cattle. However, 
this product is derived from animal origin materials, and the recombinant FSH 
technology represents the next generation of this important intervention. 

"Recombinant technology is the important next step in the production of protein 
hormones for use in cattle," said Dr. Reuben Mapletoft, Distinguished 
Professor, Department of Large Animal Clinical Sciences, Western College of 
Veterinary Medicine, University of Saskatchewan. "This process completely 
eliminates the potential for contamination with infectious agents and provides 
for a safe and highly consistent product. The efficacy of the Trophogen 
technology is very gratifying for those of us who have worked with it and 
provides for exciting possibilities for the future application of assisted 
reproductive technologies in cattle." 

About Bioniche Life Sciences Inc. 

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian 
biopharmaceutical company focused on the discovery, development, manufacturing, 
and marketing of proprietary and innovative products for human and animal 
health markets worldwide. The fully-integrated company employs more than 200 
skilled personnel and has three operating divisions: Human Health, Animal 
Health, and Food Safety. The Company's primary goal is to develop and 
commercialize products that advance human or animal health and increase 
shareholder value. 

Bioniche Animal Health develops, manufactures and markets veterinary 
biopharmaceutical products worldwide. In North America, it has development, 
manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, 
Georgia, U.S.A. and Pullman, Washington, U.S.A. In Australia, business is 
conducted from two sites: Sydney, New South Wales, where sales and marketing, 
customer support and technical service are located; and Armidale, New South 
Wales, where research, development and manufacturing facilities are located. 

Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small and 
Medium-Sized Employers in Canada for 2011. For more information, please visit 
www.Bioniche.com 

About Trophogen Inc. 

Trophogen, Inc. is a U.S.-based biotechnology company founded in 2001 with 
Series A funding from Toucan Capital, focusing on the development of human and 
bovine high affinity glycoprotein hormone and related growth factor 
superagonist analogs for human infertility and animal superovulation as well as 
targeted therapy and imaging of thyroid, ovarian, breast, prostate and 
testicular cancers. Trophogen's lead product is a long-acting human FSH 
superagonist for a multibillion dollar human infertility market, and the 
above-described bovine FSH analog was engineered to mimic the proven increased 
efficacy of the human FSH analog. In addition to its venture capital support, 
Trophogen has received a $3 million NICHD Phase 2 SBIR grant to take its human 
FSH analog to Phase I-II clinical trials in 2014. Trophogen has also received 
over $5 million from other NIH SBIR grants to take other advanced pre-clinical 
human products to Phase I-II clinical trials by 2016 for additional 
multibillion dollar markets. It has also received over $3 million from various 
human and veterinary pharmaceutical co-development and licensing agreements. 
For more information about Trophogen, please visit www.trophogen.com. 

Except for historical information, this news release may contain 
forward-looking statements that reflect the two companies' current expectations 
regarding future events. These forward-looking statements involve risk and 
uncertainties, which may cause, but are not limited to, changing market 
conditions, the successful and timely completion of clinical studies, the 
establishment of corporate alliances, the impact of competitive products and 
pricing, new product development, uncertainties related to the regulatory 
approval process, and other risks detailed from time to time in Bioniche's 
ongoing quarterly and annual reporting.

   SOURCE: Bioniche Life Sciences Inc.

   CONTACT: Jennifer Shea, 
            Vice-President, 
            Communications, Investor & Government Relations,Bioniche Life 
Sciences Inc., 
            Telephone: (613) 966-8058; 
            from Australia: 0011 1 613-966-8058, 
            Cell: (613) 391-2097; 
            from Australia: 0011 1 613-391-2097, 
            Jennifer.Shea@Bioniche.com
            (BNC.)